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Summary Oestrogen (ER) and progestin receptors (PR) were measured in cytosols from histologically normal
mammary tissues (n=30), and in benign (n=59) and malignant mammary lesions (n=49) from female dogs.
Receptor levels .5 fmol mg- 1 protein were considered positive. The presence of histologically normal
mammary epithelium within specimens of primary tumours was noticed as a factor that may cause false-
positive receptor results. Receptor levels in non-malignant tissues, and the receptor status of primary cancers
did not vary significantly with regard to the phase of oestrous cycle (anoestrus/metoestrus) or the influence of
exogenous progestins. ER- or PR-positivity was more frequent and levels of both receptors were higher in
'normal' tissues and in benign lesions than in primary cancers (P<0.001). ER and PR levels were higher in
benign lesions of dogs also developing malignant mammary tumours than in benign lesions of dogs that did
not (P<0.02 and P<0.05, respectively). Regional and distant cancer metastases were frequently receptor-
negative. In some dogs heterogeneity of receptor status was found between different sites of the same cancer.
These findings indicate that in non-malignant mammary tissues of adult female dogs expression of the
genes encoding ER and PR is common. In malignant tumours this property may become lost, in particular in
advanced states of disease.
Mammary cancer in the dog and in the human have several
features in common, including the spontaneous occurrence
and the sparing effect of ovariohysterectomy if performed
early in life (Schneider et al., 1969, Feinleib, 1968). Oestrogen
(ER) and progestin receptors (PR) have been found in a
large proportion of mammary cancers in both species
(Raynaud et al., 1981; McGuire et al., 1982; Pierrepoint et
al., 1984), indicating a role for sex steroid hormones in
growth of such tumours. The receptor status of human
breast cancer has become established as a useful predictor of
the likelihood of response of the disease to endocrine
therapy (McGuire et al., 1982) and has also been found to
be related to the degree of differentiation (Fisher et al.,
1987). These observations may be interpreted as indications
that steroid receptor presence in a tumour reflects persistence
of normal cell characteristics. It has been difficult, however,
to detect substantial amounts of ER in adult normal human
breast tissue (Wagner & Jungblut, 1976). This has led to the
reverse view, namely, that expression of hormone receptors
reflects a feature related to the process of neoplastic trans-
formation (Israel & Band, 1984).
The present study was undertaken in order to determine
the ER and PR profile of histologically non-affected mam-
mary glands and of benign and malignant (primary and/or
metastatic) proliferative lesions in the dog. Results were
related to histopathological and some clinical features of
affected dogs. Results of a limited number of these deter-
minations have been included in other reports (Rutteman &
Misdorp, 1986; Rutteman et al., 1986, 1988).
Materials and methods
Animals and tissues
ER and PR analyses were performed in mammary tissues
obtained at surgery or autopsy from female dogs of various
breeds or mixed breed. Histologically non-affected mammary
tissues (n =30) were studied in 30 dogs with mammary
disease. Histologically benign proliferative lesions (n =59)
were analysed in 45 dogs, and malignant tumours (n =49)
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in 47 dogs, including 8 animals where both types of lesion
were assayed. Many dogs developed multiple lesions.
Those that were not used for ER/PR analysis were always
examined histopathologically.
Tumour treatment consisted of surgery alone. Care was
taken to document the simultaneous or sequential occurrence
of mammary cancer in dogs presenting with benign lesions.
After surgery for the latter, dogs were followed for at least
12 months (median 22, range 12-48 months) or until malig-
nant disease was recognized. Clinical staging of dogs with
cancer was done on the basis of the WIlO TNM classifi-
cation for tumours in domestic animals (Owen, 1980), where
T stands for tumour condition, N for the condition of the
regional lymph nodes and M for the absence/presence of
distant metastasis (including distant nodes). Regional lymph
nodes were considered involved only if tumour deposits were
found at cytological or histological examination.
Reproductive cycle and progestin use
The phase of the oestrus cycle was assessed by combining
physical signs and determinations of plasma progesterone
(P4) concentrations (Dieleman et al., 1979), allowing for the
following classification: Anoestrus: no signs of oestrus,
P4<6,umol 1-1; (pro-) oestrus: period of haemorrhagic vul-
var discharge, P4<25 imol1-1; metoestrus: period following
oestrus, P4.6pmoll-1. Treatment of dogs with long-acting
injectable progestins (medroxyprogesterone acetate: Depo-
promone, Upjohn, Ede, The Netherlands, or proligestone,
Gist Brocades, Delft, The Netherlands) was categorized as
ever vs. never and influence was defined as: Rresent: last
injection <51 months ago; uncertain: last injection 51 7
months ago, negligible: last injection >7 months ago. In the
last case, the dogs were categorized according to oestrous
cycle phase. The results from (pro-) oestrus and from
uncertain progestin influence were excluded in analyses of
the effect of phase of the reproductive cycle or of progestin
treatment, because of paucity of data.
Tissues
Upon surgery or autopsy - the latter always being completed
within 30min following euthanasia - tissues were immedi-
ately placed in melting ice. Macroscopically tumorous and
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normal tissues, well separated from the former, were partly
dissected, cleared of fat and necrotic parts and cut in blocks
of +0.5cm diameter. Several blocks and the remaining
specimen were fixed in 10% formalin for histopathological
analysis and classification, according to WHO guidelines
(Hampe & Misdorp, 1974). The other blocks were frozen
quickly in liquid nitrogen and stored at -70°C. Receptor
analysis was performed within one month.
Analysis of non-affected mammary tissues (further referred
to as normal tissues) has been confined to those that did not
have areas of proliferative disorder at microscopic exami-
nation. The relative proportion of epithelial plus myoepi-
thelial cells was assessed as percentage of tissue occupied in
microscopic sections. Tumour specimens were analysed only
if the proportion of viable tumour cells was .10%.
The group of benign proliferative lesions consisted of 11
lobular simple (epithelial) or complex (epithelial +myoepi-
thelial) hyperplasias, 1 intraductal papilloma, 28 simple or
complex adenomas, 6 fibroadenomas and 13 benign mixed
tumours. The group of infiltrating cancers consisted of 7
simple tubular adenocarcinomas, 2 simple and 2 complex
papillary adenocarcinomas, 19 simple and 3 complex solid
carcinomas, 11 anaplastic carcinomas, 2 fibrosarcomas and 3
carcinosarcomas.
Histological grading of carcinomas and sarcomas was
performed as described (Misdorp, 1976).
Steroid receptor analysis
ER and PR content and affinity were determined in the high
speed cytosol of a sample by the multi-concentration
dextran-coated charcoal method published previously
(Rutteman et al., 1986) with computation according to
Scatchard (1949). High affinity binding was considered
present if the dissociation constant of the binding reaction
(Kd) was <5lx10-1°M for ER and <5x 10-9M for PR. A
value of .5fmolmg-1 cytosolic protein was taken as posit-
ive (ER+ and PR+, respectively). Lower values were con-
sidered negative (ER- and PR-, respectively).
At histological examination some samples of primary
tumours were found to contain not only tumour but also
histologically normal mammary epithelium, recognized on
the basis of architectural features and lack of cellular atypia.
Since normal mammary tissues frequently contain consider-
able ER and PR activity (Rutteman & Misdorp, 1986, and
Results), data on tumour specimens with normal mammary
epithelium are considered liable to bias and therefore pre-
sented separately.
Data presentation and statistical analysis
In studies where receptor status and levels were compared
with other features recognized within tissue specimens, all
specimens of a given diagnostic class of tissues were used.
However, twelve dogs had 2 or 3 benign lesions assayed; on
comparing receptor data with host factors or between differ-
ent tissue classes, one specimen of this class was at random
chosen to represent one animal. The Spearman rank-
correlation test was applied to test the correlation of two
variables. The Wilcoxon rank-sum test was used for the
analysis of differences between medians of data groups. The
Fisher exact test for a dichotomy was used to test differences
in frequency distribution in data groups. The level of
significance was set at a P value of 0.05.
Results
Normal mammary gland tissues
Normal mammary gland specimens (n =30) were analysed in
30 intact female dogs, 3-12 years of age (median 94 years).
Twenty-nine of these had positive ER and PR levels (Table
I). The ER and PR levels were proportional (Figure 1). No
significant correlation was found between age and ER con-
centrations (r=0.21, P=NS), whereas a weak positive corre-
lation was found between age and PR concentrations
(r=0.37, P<0.05). Epithelium content (%SA =percentage of
surface area in microscopic sections occupied by epithelial
plus myoepithelial cells) was not correlated with ER levels
nor with PR levels (r=0.07 and -0.18, respectively). Speci-
mens obtained in the phase of exogenous progestin influence
as well as those in metoestrus had an increased epithelium
content (%SA) as compared to those obtained in an oestrus,
however, the latter difference was not significant (Figure 2).
Levels of ER or of PR did not vary significantly between
these three phases, although median values were highest in
metoestrus (Figure 2). Dogs ever treated with injectable
progestins did not have significantly different ER or PR
levels from dogs never treated with such compounds (data
not shown).
Benign proliferative lesions
Fifty-nine benign proliferative lesions were examined in 45
dogs. Five of these had been spayed, the others were intact
female dogs. The age ranged from 61-12 years (median 9
years).
In 6 benign lesions, all containing both ER and PR
activity (Table I), the presence of normal mammary epi-
thelium was noticed. These data were considered to be
susceptible to bias and were not further analysed. Forty-nine
of the remaining 53 benign lesions (in 41 dogs) were
ER+PR+ (Table I). Within the group of 'pure' benign
lesions the ER and PR levels were proportional (Figure 1).
Epithelium content (%SA) and ER levels were very weakly
but significantly correlated (r=0.28, P<0.05), whereas the
correlation of this factor with PR levels was not significant
(r=0.22, P=NS).
Of dogs (n=10) with more than one benign lesion
assayed, one specimen was chosen at random to represent
that particular animal in comparisons of host factors with
receptor data. These comparisons could thus be performed
in 41 animals. No correlation was found between dog age
Table I ER and PR status and concentration in histologically normal mammary glands, in benign proliferative lesions, and in primary
malignant tumours
ER(fmolmg protein) PR(fmolmg protein)
Number of ER+ PR+ ER+PR+
Tissue specimens (n) (n) (n) median (range) median (range)
Normal mammary gland 30 29a 29a 29a 52a (0-189) 45a (0-263)
Benign 53 50a 49a 49a 53a (0-139) 85axc (0-546)
Benign/normal mixture 6 6 6 6 60 (57-187) 135 (79-423)
Malignant 23 13 12 10 6 (0- 59) 9 (0-200)
Malignant/normal mixture 18 17b 16b 15b 16b (0-138) 23b (0-132)
Malignant/benign mixture 3 3 3 3 21 (18- 23) 60 (46- 97)
The limit for receptor positivity was taken to be 5 fmolmg-I cytosolic protein. Specimens composed of a mixture of different tissue classes
were not included in the statistical analysis, except for the comparison ofmalignant vs. malignant/normal mixture. aSignificantly different from
malignant tissue value at P<0.001, or bat P<0.02. cSignificantly different from normal tissue value at P<0.02. Kd values were
1.2+0.3 x 10-10M (ER, mean+s.e.) and 0.7+0.1 x 10-9 M (PR, mean+s.e.), and did not vary significantly among the three main classes of
tissue.
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Figure 1 The relationship between oestrogen (ER) and proges-
tin receptor (PR) concentrations in dog mammary tissues.
Statistically significant correlations were found for histo-
logically normal mammary glands (NMG, r=0.67,
P<0.0001), benign lesions (BL, r=0.63, P<0.0001) and
primary malignant tumours (MT, r=0.68, P<0.01). After
exclusion of ER-PR- samples (outside the dashed lines)
this significance was lost only for MT (r=0.38, P=0.18).
Note: for BL and MT only specimens not intermeshed with
normal mammary epithelium were considered.
and ER (r= -0.17, P=NS) or PR levels (r -0.16,
P=NS). No difference was found in epithelium content
(%SA) with regard to phase of the oestrus cycle or phase of
exogenous progestin influence (Figure 2). Neither was a
significant variation established in ER or in PR levels among
these phases, although median values were highest in met-
oestrus (Figure 2). The results from dogs in the phase of
uncertain exogenous progestin influence (n =4) and from
spayed dogs (n=3) were too few in number to be considered
in this comparison. Dogs ever treated with progestins
(n = 13) did not have ER or PR concentrations significantly
different from dogs that had never been treated (n=28, data
not shown).
The development of malignant mammary tumours before,
simultaneously with, or after operation upon benign lesions
was established in 14 dogs, whereas 24 dogs remained free
from signs of mammary cancer. Three animals were lost at
follow-up. Concentrations of both receptors were found to
be higher in benign lesions of dogs also developing mam-
mary cancer (ER, median 71, range 26-123 fmolmg-1 pro-
tein; PR, median 136, range 25-546fmolmg-1 protein) than
of those that did not (ER, median 39, range 0-
lOOfmolmg-1 protein, P<0.02; PR, median 65, range 0-
371 fmolmg-1 protein, P<0.05). Median epithelium content
was equal in both groups.
ER levels in the 'pure' benign lesions were similar to those
in normal tissues, whereas PR levels were distinctly higher in
the former (Table I). This result was found both when this
comparison was performed with the complete group of
benign lesions as well as with the reduced group in which
one specimen was chosen at random per animal (difference
in PR levels for both conditions, P<0.02).
Malignant tumours
This group consisted of 49 tumours in 47 dogs. Receptor
assays were performed in 44 primary growths of 42 dogs;
two dogs had bilateral cancers. In 5 dogs the primary
tumour was not available for receptor assay: in these cases
metastatic sites only (n=3) or combined with locally recur-
rent lesions (n=2) were examined.
In 3 primary cancers malignant areas were found together
with histologically benign tumour structures. In another 18
primary cancers the presence of normal mammary epithelium
was noticed. Receptor results of these, mainly ER+PR+,
'non-pure' tumours were considered susceptible to bias.
Indeed, a positive status for ER as well as for PR was more
frequent in 'non-pure' primary cancers and levels of both
receptors were higher than in 'pure' cancer specimens
(Table I).
The 23 'pure' primary cancers (23 dogs) were studied in
more detail. The age at first presentation ranged from 5-13
years (median 9 years). Three of the dogs had been spayed,
the others were intact female dogs. ER and PR-positivity
was less frequent and the levels were lower than in normal
mammary tissues or in 'pure' benign lesions (Table I). The
latter comparisons held true when performed with the com-
plete group of benign lesions and with the one specimen/
animal group.
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Figure 2 Epithelium content (left) and oestrogen (ER, middle) and progestin receptor (PR) concentrations (right) of histologically
normal mammary glands (NMG: 0) and benign lesions without normal epithelium (BL: 0), obtained in anoestrus (AN),
metoestrus (MET) or during presence of exogenous progestin influence (P+). The median value is indicated by a horizontal line.
Epithelium content (%SA=assessed as percentage of tissue occupied in microscopic sections) of normal tissue was significantly
higher in P+ (P<0.002) and tended to be higher in MET (P=0.085) compared to AN. No such variation was found for benign
lesions with regard to these phases. ER and PR concentrations did not differ significantly between the respective phases for both
tissue classes.
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Metastases
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Table II ER and PR statu
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Tumour site (n)
Primary cancer2
RLN
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23
15
12
ldc, discordance of either:
metastases. RLN, regional
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aER or PR negativity occu
distant metastases than in pr
Table III Comparison of E
metastatic mammary
Dogs
Tumour sites (n) +
Local I vs. RLN
ER 6
PR 6
Local vs. DM
ER 5
PR 5 1
1Local, primary or locally
as in Table II.
Note: this comparison was
status of regional and/or di,
primary (n=6) or locally r
intermeshed with normal ma
- found to be correlated (r=0.68,
R-PR- cases were excluded, this
Discussion
;er significant (r=0.38, P=NS). Histologically normal mammary tissue was found to contain
SA) was not proportional to ER ER as well as PR in nearly all the dogs in this study, in
y (r= -0.005). No association was contrast to earlier negative findings (Hamilton et al., 1977;
and ER (r=0.17) or PR level Elling & Ungemach, 1983). ER- and PR-positivity has also
(ses in this group were confined to been demonstrated in mammary tissue of normal dogs
ical assessment of the relation of (d'Arville, 1979; Bergink et al., 1980). ER and PR levels
(ogenous progestin influence with given in these latter reports, as well as those found by us in
ted, since the number of cases in 5 two-year-old normal beagle bitches (unpublished results)
)o low. However, no pattern of were in the same range as those determined in the present
apparent (data not shown). series. Thus, it is not likely that the level of expression of ER
stage: in stage I-III cancers (Mo, and PR in unaltered tissue oftumour-bearing dogs differs from
17) the size of the primary tumour that of normal dogs.
PR status (not shown). ER+ or The increased epithelium content during progestin treat-
vere found in 2 of 3 dogs with ment or in metoestrus compared to that in anoestrus may
Ivement and in 10 (ER) and 9 (PR) reflect the high proliferative activity of glandular epithelium
involvement respectively. However, that is known to occur in the dog during progestin exposure
ogs with stage IV (M1) disease a (Bergink et al., 1984; Spanel-Borowski et al., 1984). In
f PR (5/6) was somewhat more contrast, no such increase was observed in benign lesions. In
of dogs with stage 1-111 disease addition, ER or PR levels in normal tissues or in benign
-: 8/17, P=0.14). lesions did not vary significantly with regard to anoestrus or
n in ER or PR status was seen metoestrus or period of exogenous progestin influence. In
,ical malignancy grades or nuclear dog uterus, ER and PR levels have been found to rise
several-fold during the period of follicular oestrogen secre-
tion above values in anoestrus. In metoestrus a decrease
occurs to values slightly below those in anoestrus (Johnston
)ntent was determined in metastatic et al., 1985). It remains to be established whether receptor
nscollected at surgery or autopsyi levels in dog mammary tissues are elevated during the
ns
collect a dogsureryford atops follicular phase, as in the uterus. nodes (15 dogs) were found to be. .
than one third of cases. Distant Epithelium content was not correlated with ER or PR
,) rarely expressed either receptor quantity in normal tissues. A weak correlation was found
astases (regional/regional +distant/ between epithelium content and ER quantity in benign
2 dogs. Heterogeneity in ER or PR lesions. In expressing receptor levels on the basis of protein
dses of the same dog was observed content in the cytosol, however, a correction factor is
als respectively. already applied, at least partly (Mason et al., 1982), for Iancsrespectively with regional or differences in cellularity of tissue specimens.
cdthat receptor-negative status was The proportion of ER- and PR-positive benign lesions in
a change from a positive to a the dog observed by us and some others (MacEwen et al.,
aed in some of the dogs (TabletI)a 1982; Inaba et al., 1984) is higher than that reported e elsewhere (Hamilton et al., 1977; Raynaud et al., 1981;
Pierrepoint et al., 1984). Receptor levels of positive cases, in
general, are in the same range in all these studies.
ER status PR status The high frequency of receptor-positivity in unaltered
mammary tissue found by us in the dog, is in contrast with
+ - dc' + - dc observations in man (Wagner & Jungblut, 1976;
13 10 - 12 11 - Kouyoumdjian et al., 1986). A greater epithelium content in
4 10 1 3 11 1 dog mammary tissues as compared to that present in man
- I la I 1 1 a _ (Hutson et al., 1985) may contribute to such a difference.
ER or PR status between two or more Yet, even if procedures are followed that ensure a high
lymph node metastasis. DM, distant epithelial density in samples of normal human breast (Silva
without normal mammary epithelium. et al., 1983) the ER or PR levels seem to be lower than those
irred significantly more frequently in measured in the dog. A similar difference is found in the
rimary cancers (P<0.02). comparison of dog benign proliferative lesions and human
fibrocystic disease or fibroadenomas (Allegra et al., 1979;
Brentani et al., 1986). However, ER and PR presence and
RcandcPrsitats betwesamen local
a levels in benign lesions of the human breast with marked cancer sites in the same dog proliferative activity (Martin et al., 1978; Jacquemier et al.,
Change in status 1982), appear to follow a pattern similar to that observed by
us in the dog. >+ +-* -~+ -+ - .dc A further difference between the two species is the often
pronounced attribution of the myoepithelium in proliferative
2 4 mammary disease in the dog (Hampe & Misdorp, 1974). It
2 4 - will be of interest to investigate the responsiveness of this cell
type in the dog to growth regulatory factors, e.g., by
2 2 1 immunohistochemical methods that can visualize steroid
I _ 3 - receptors.
Our finding of an increased PR level in dog benign lesions
recurrent cancer; further abbreviations compared to unaltered tissues is of interest, in view of the
made in 8 dogs in which ER and PR reported mammary tumour-promoting influence of pro-
stant sites could be related to that of gestins in this species (Casey et al., 1979). In addition, the
'ecurrent (n=2) cancer specimens not increase in ER and PR levels in benign lesions of dogs that
[mmary epitheliums. also developed malignant tumours compared to those that598 G.R. RUTTEMAN et al.
did not, may indicate an enhancement in the phenotypic
expression of hormone receptors in tissues engaged in the
process of malignant transformation (Cikes, 1978). If true,
then this enhancement may disappear in a later stage of this
process: low receptor levels as well as low proportions of
receptor-positive cases were found in primary cancers, as
compared to non-malignant tissues. Metastatic sites were
infrequently receptor-positive.
Thus, steroidal regulatory influence may be more likely to
remain intact in non-cancerous than in cancerous states. A
similar pattern of receptor distribution has been found in
measurements of specific binding of prolactin in dog mam-
mary tissues (Rutteman et al., 1986). In the human, steroid
receptor positivity of cancer metastases is more common,
and receptor levels both in primary cancers as well as in
metastases are often higher (Vihko et al., 1980; Wittliff,
1984), than in our series of dog cancers. This may indicate
that in the dog, a loss of hormone dependency occurs at an
earlier stage than in man. Yet, loss of ER or PR may also
occur in human breast cancer (not treated with endocrine
measures) at progression of the disease towards overt meta-
stasis (Osborne, 1983). Furthermore, in primary human
breast cancer, the presence of steroid receptors is positively
correlated with state of differentiation (Fisher et al., 1987).
Thus, more malignant conditions may be more often steroid
receptor-negative in both species.
In conclusion, unaltered mammary tissues and benign
lesions in the dog frequently contain both ER and PR. This
feature is less common in primary cancers and infrequent in
distant metastases. This indicates a change from steroid
hormone dependency towards independency with dedifferen-
tiation and progression of mammary tumour disease.
Increased production of growth factors and/or growth
factors receptors may be one of the mechanisms by which
tumour cells overcome steroid hormone dependency
(Dickson & Lippman, 1986).
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